drugset
drugset / Trial / NCT04220996

Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

NCT04220996 ↗

Phase 4 Completed 100 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.

Timeline

Start
2019-12-27
Primary completion
2021-03-09
Completion
2021-03-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral

Indications

anxiety disorder major depressive disorder